NGM Biopharmaceuticals names new president and CFO
This article was originally published in Scrip
Executive Summary
San Francisco–based, privately held NGM Biopharmaceuticals has appointed Jeff Jonker president, and Dr David Woodhouse chief financial officer, both effective immediately. The appointments are aimed at expanding the company in line with its collaboration with Merck & Co. Mr Jonker was previously senior vice-president of corporate and business development at Theravance, and has also held leadership positions at Genentech and Satori Pharmaceuticals. Dr Woodhouse joins NGM from Goldman Sachs where he was managing director and co-head of US biotechnology investment banking.